Hedging Your Bets: A Resident’s Guide to Hedgehog Inhibitors for laBCC
About this episode
The episode explores locally advanced basal cell carcinoma and the role of Hedgehog inhibitors in treatment, featuring insights from Dr. Meenal Kheterpal.
In this episode of Cutaneous Miscellaneous, host Nicholas Brownstone, MD, welcomes Meenal Kheterpal, MD, Associate Professor of Dermatology at Duke University School of Medicine, for a comprehensive look at locally advanced basal cell carcinoma (laBCC) and the role of Hedgehog inhibitors (HHIs), a must-know topic for dermatology residents. Dr Brownstone opens with a board review of basal cell carcinoma, including risk factors, clinical variants, treatment selection, and when to consider Mohs surgery. He breaks down the Hedgehog signaling pathway, explaining how vismodegib and sonidegib work and their common side effects. In the main segment, Dr Kheterpal discusses how to identify and define laBCC in clinical practice, select appropriate candidates for HHI therapy, and integrate these agents into neoadjuvant treatment strategies. She shares practical pearls on counseling patients, managing adverse effects like muscle cramps, alopecia, and dysgeusia, and addressing teratogenicity concerns in reproductive-age patients. The episode also highlights tips for communicating treatment expectations confidently and applying clinical judgment beyond textbook definitions. Tune in to the full…
More episodes of Cutaneous Miscellaneous: The Dermatology Residents Podcast
- From Exhibit Hall to Emerging Data: A Resident’s AAD Annual Meeting Playbook
- Beyond the Prescription Pad: The Clinical Power of OTC Skin Care
- From Residency to Real Life: Avoiding Burnout Before It Starts
- Teamwork Makes the Skin Work: Your Guide to Clinic Culture
- Light Work: PDT Made Simple for Residents
- Hitting the JAKpot: New Frontiers in Alopecia Areata
Explore listener stats, chart rankings, contacts and more on the Cutaneous Miscellaneous: The Dermatology Residents Podcast podcast page.